Alzheimer's drug shows promise in imaging study

02/28/2010 | Reuters

Bapineuzumab, an experimental drug being developed by Pfizer, Elan and Johnson & Johnson, appeared to reduce beta amyloid buildup in the brain by about 25% in Alzheimer's disease patients, according to a study. Researchers used carbon-11-labeled Pittsburgh compound B, an imaging agent that binds with clogged areas of the brain.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
In house Compliance Officer
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC